Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cancer Côte d'or registry | UNKNOWN |
| Cancer Calvados registry | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.
Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit.
To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with ovarian epithelial cancer | Ovarian epithelial cancer diagnosed in 2012 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient with ovarian epithelial cancer | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained | To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment | 2 years after diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained. | 2 years after diagnosis | |
| Budget impact analysis | Cost assessment performed retrospectively for each patient: hospital stays, visits and other health-related costs will be identified and measured based on the French national Health Insurance perspective. QALY (Quality-Adjusted Life Year) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Women with ovarian epithelial cancer diagnosed in 2012
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Isabelle RAY-COQUARD, PU-PH | Centre Leon Berard | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Calvados registry | Caen | France | ||||
| Côte d'or registry |
Not provided
| ID | Term |
|---|---|
| D000077216 | Carcinoma, Ovarian Epithelial |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 years after diagnosis |
| Relapse-free survival (RFS) | RFS will be assessed 2 years after diagnosis |
| Dijon |
| France |
| Oveval | Lyon | France |
| D010051 |
| Ovarian Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |